tubastatin A [Ligand Id: 9702] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL2018302 (Tubastatin A)
  • histone deacetylase 1/Histone deacetylase 1 in Human [ChEMBL: CHEMBL325] [GtoPdb: 2658] [UniProtKB: Q13547]
  • histone deacetylase 1/Histone deacetylase 1 in Mouse [ChEMBL: CHEMBL4001] [GtoPdb: 2658] [UniProtKB: O09106]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 10/Histone deacetylase 10 in Human [ChEMBL: CHEMBL5103] [GtoPdb: 2614] [UniProtKB: Q969S8]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 11/Histone deacetylase 11 in Human [ChEMBL: CHEMBL3310] [GtoPdb: 2615] [UniProtKB: Q96DB2]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 2/Histone deacetylase 2 in Human [ChEMBL: CHEMBL1937] [GtoPdb: 2616] [UniProtKB: Q92769]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 3/Histone deacetylase 3 in Human [ChEMBL: CHEMBL1829] [GtoPdb: 2617] [UniProtKB: O15379]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 3/Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) in Human [ChEMBL: CHEMBL2111363] [GtoPdb: 2617] [UniProtKB: O15379Q9Y618]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 4/Histone deacetylase 4 in Human [ChEMBL: CHEMBL3524] [GtoPdb: 2659] [UniProtKB: P56524]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 5/Histone deacetylase 5 in Human [ChEMBL: CHEMBL2563] [GtoPdb: 2660] [UniProtKB: Q9UQL6]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 6/Histone deacetylase 6 in Human [ChEMBL: CHEMBL1865] [GtoPdb: 2618] [UniProtKB: Q9UBN7]
  • histone deacetylase 6/Histone deacetylase 6 in Mouse [ChEMBL: CHEMBL2878] [GtoPdb: 2618] [UniProtKB: Q9Z2V5]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 7/Histone deacetylase 7 in Human [ChEMBL: CHEMBL2716] [GtoPdb: 2661] [UniProtKB: Q8WUI4]
There should be some charts here, you may need to enable JavaScript!
  • Histone deacetylase 8 in Schistosoma mansoni [ChEMBL: CHEMBL3797017] [UniProtKB: A5H660]
  • histone deacetylase 8/Histone deacetylase 8 in Human [ChEMBL: CHEMBL3192] [GtoPdb: 2619] [UniProtKB: Q9BY41]
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 9/Histone deacetylase 9 in Human [ChEMBL: CHEMBL4145] [GtoPdb: 2620] [UniProtKB: Q9UKV0]
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
histone deacetylase 1/Histone deacetylase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL325] [GtoPdb: 2658] [UniProtKB: Q13547]
ChEMBL Inhibition of human HDAC1 B 5.42 pKi 3823.3 nM Ki Bioorg Med Chem (2015) 23: 5151-5155 [PMID:25637120]
ChEMBL Inhibition of human recombinant HDAC1 using RHKKAc peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs B 4.79 pIC50 16400 nM IC50 J Med Chem (2012) 55: 639-651 [PMID:22165909]
ChEMBL Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate B 4.79 pIC50 16400 nM IC50 J Med Chem (2012) 55: 9891-9899 [PMID:23009203]
ChEMBL Inhibition of human recombinant HDAC1 protein using RHKKAc from p53 as substrate B 4.79 pIC50 16400 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.79 pIC50 16400 nM IC50 J Med Chem (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC1 using RHKKAc as substrate B 4.79 pIC50 16400 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.79 pIC50 16400 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Inhibition of HDAC1 (unknown origin) B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2015) 96: 340-359 [PMID:25899338]
ChEMBL Inhibition of HDAC1 (unknown origin) B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of human recombinant full-length HDAC1 (1 to 482 residues) expressed in baculovirus using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of HADC1 (unknown origin) B 4.79 pIC50 16400 nM IC50 J Med Chem (2020) 63: 23-39 [PMID:31415174]
ChEMBL Inhibition of recombinant human HDAC1 using RHKKAc fluorogenic peptide substrate B 4.79 pIC50 16400 nM IC50 J Med Chem (2019) 62: 1138-1166 [PMID:30645113]
ChEMBL Inhibition of human HDAC1 using p53 fluorogenic peptide (379 to 382 residues) RHKKAc as substrate by fluorescence-based assay B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2018) 143: 1406-1418 [PMID:29133060]
ChEMBL Inhibition of HDAC1 (unknown origin) B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of recombinant human HDAC1 using Fluor de Lys-SIRT1 as substrate incubated for 15 mins by fluorescence assay B 4.84 pIC50 14350 nM IC50 Eur J Med Chem (2016) 116: 126-135 [PMID:27060764]
GtoPdb - - 4.86 pIC50 13800 nM IC50 US8748451. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.86 pIC50 13800 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 expressed in Sf21 cells using RHKK(Ac) as substrate after 60 mins by fluorimetric method B 5 pIC50 >10000 nM IC50 Eur J Med Chem (2017) 127: 115-127 [PMID:28038324]
ChEMBL Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay B 5 pIC50 >10000 nM IC50 Bioorg Med Chem (2020) 28: 115250-115250 [PMID:31924504]
ChEMBL Inhibition of HDAC1 (unknown origin) B 5.09 pIC50 8100 nM IC50 J Med Chem (2020) 63: 10246-10262 [PMID:32815366]
ChEMBL Inhibition of human full length recombinant HDAC1 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 5.1 pIC50 8000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
ChEMBL Inhibition of HDAC1 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay B 5.12 pIC50 7582.5 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of recombinant human HDAC1 using Z-(Ac)-Lys-AMC as substrate incubated for 40 mins by fluorescence based assay B 5.15 pIC50 7048 nM IC50 Eur J Med Chem (2021) 218: 113392-113392 [PMID:33831778]
ChEMBL Inhibition of HDAC1 (unknown origin) measured after 30 mins by fluorescence microplate reader assay B 5.3 pIC50 >5000 nM IC50 J Med Chem (2021) 64: 15280-15296 [PMID:34624191]
ChEMBL Inhibition of recombinant human KDAC1 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay B 5.54 pIC50 2870 nM IC50 J Med Chem (2016) 59: 1613-1633 [PMID:26681404]
ChEMBL Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 5.57 pIC50 2700 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of HDAC1 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 5.57 pIC50 2700 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay B 5.6 pIC50 2490 nM IC50 Medchemcomm (2019) 10: 1109-1115 [PMID:31391882]
ChEMBL Inhibition of human recombinant HDAC1 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay B 5.6 pIC50 2490 nM IC50 J Med Chem (2020) 63: 10339-10351 [PMID:32803970]
ChEMBL Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis B 5.7 pIC50 >2000 nM IC50 Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925]
ChEMBL Inhibition of recombinant C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using fluorogenic ZMAL as substrate incubated for 90 mins by fluorescence assay B 5.72 pIC50 1910 nM IC50 J Med Chem (2019) 62: 1138-1166 [PMID:30645113]
ChEMBL Inhibition of full length C-terminal His/FLAG-tagged human HDAC1 expressed in baculovirus expression system using ZMAL as substrate incubated for 90 mins by fluorescence assay B 5.72 pIC50 1910 nM IC50 ACS Med Chem Lett (2020) 11: 2268-2276 [PMID:33214839]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.85 pIC50 1400 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis B 5.95 pIC50 1109.7 nM IC50 Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925]
ChEMBL Inhibition of human HDAC1 pre-incubated for 5 mins before substrate addition and measured after 30 mins by fluorescence based assay B 6.12 pIC50 752 nM IC50 J Med Chem (2021) 64: 1116-1126 [PMID:33356256]
ChEMBL Inhibition of HDAC1 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.84 pIC50 144 nM IC50 J Med Chem (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 1/Histone deacetylase 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4001] [GtoPdb: 2658] [UniProtKB: O09106]
ChEMBL Inhibition of HDAC1 in mouse N2A cells B 5.09 pIC50 8100 nM IC50 ACS Med Chem Lett (2020) 11: 706-712 [PMID:32435374]
histone deacetylase 10/Histone deacetylase 10 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5103] [GtoPdb: 2614] [UniProtKB: Q969S8]
ChEMBL Inhibition of HDAC10 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC10 using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of N-terminal GST-tagged human HDAC10 (1 to 481 residues) using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC10 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of HDAC10 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC10 protein using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human full length recombinant HDAC10 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 4.6 pIC50 25000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.43 pIC50 3710 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of tubastatin-Alexa647-tracer binding to recombinant GST-tagged HDAC10 (unknown origin) measured after 1 hr by TR-FRET assay B 7.9 pIC50 12.59 nM IC50 J Med Chem (2019) 62: 4426-4443 [PMID:30964290]
ChEMBL Inhibition of dye-labeled tracer binding to HDAC10 (unknown origin) transfected in human HeLa cells measured after 2 hrs by nano-luciferase reporter gene-based BRET assay B 7.9 pIC50 12.59 nM IC50 J Med Chem (2019) 62: 4426-4443 [PMID:30964290]
histone deacetylase 11/Histone deacetylase 11 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3310] [GtoPdb: 2615] [UniProtKB: Q96DB2]
ChEMBL Inhibition of HDAC11 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC11 using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of full length N-terminal GST-tagged human HDAC11 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of human recombinant HDAC11 protein using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of HDAC11 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of HDAC11 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human full length recombinant HDAC11 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 4.8 pIC50 16000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
ChEMBL Inhibition of recombinant human HDAC11 measured after 30 mins by fluorescence microplate reader assay B 5.3 pIC50 >5000 nM IC50 J Med Chem (2021) 64: 15280-15296 [PMID:34624191]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.42 pIC50 3790 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
histone deacetylase 2/Histone deacetylase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1937] [GtoPdb: 2616] [UniProtKB: Q92769]
ChEMBL Inhibition of C-terminal GST-tagged recombinant human HDAC2 (1 to 488 residues) expressed in Baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay B 5.24 pKi 5770 nM Ki Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326]
ChEMBL Inhibition of human recombinant full-length C-terminal GST-tagged HDAC2 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC2 protein using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC2 using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of full length C-terminal 6x-His tagged human HDAC2 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC2 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of human HDAC2 using p53 fluorogenic peptide (379 to 382 residues) RHKKAc as substrate by fluorescence-based assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2018) 143: 1406-1418 [PMID:29133060]
ChEMBL Inhibition of HADC2 (unknown origin) B 4.52 pIC50 >30000 nM IC50 J Med Chem (2020) 63: 23-39 [PMID:31415174]
ChEMBL Inhibition of HDAC2 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of human full length recombinant HDAC2 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 4.72 pIC50 19000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
ChEMBL Inhibition of full length human recombinant C-terminal GST-tagged HDAC2 expressed in insect cells using RHKK(Ac) as substrate after 60 mins by fluorimetric method B 5 pIC50 >10000 nM IC50 Eur J Med Chem (2017) 127: 115-127 [PMID:28038324]
ChEMBL Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay B 5 pIC50 >10000 nM IC50 Bioorg Med Chem (2020) 28: 115250-115250 [PMID:31924504]
ChEMBL Inhibition of HDAC2 (unknown origin) using Ac-LeuGlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition and further incubated for incubated for 1 hrs by fluorescence microtiter plate reader assay B 5.06 pIC50 8674.5 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.2 pIC50 6270 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC2 (unknown origin) measured after 30 mins by fluorescence microplate reader assay B 5.3 pIC50 >5000 nM IC50 J Med Chem (2021) 64: 15280-15296 [PMID:34624191]
ChEMBL Inhibition of HDAC2 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 5.41 pIC50 3900 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 5.41 pIC50 3900 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of HDAC2 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.44 pIC50 360 nM IC50 J Med Chem (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 3/Histone deacetylase 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1829] [GtoPdb: 2617] [UniProtKB: O15379]
ChEMBL Inhibition of HDAC3 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of full length C-terminal 6x-His tagged human HDAC3 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC3 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of human recombinant full-length C-terminal GST-tagged HDAC3 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of HADC3 (unknown origin) B 4.52 pIC50 >30000 nM IC50 J Med Chem (2020) 63: 23-39 [PMID:31415174]
ChEMBL Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 5.54 pIC50 2900 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of HDAC3 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 5.54 pIC50 2900 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of HDAC3 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.81 pIC50 155 nM IC50 J Med Chem (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 3/Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2111363] [GtoPdb: 2617] [UniProtKB: O15379Q9Y618]
ChEMBL Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of human full length recombinant HDAC3/ NcoR2 using p53 (379 to 382 residues) (RHKK(Ac)AMC) as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 5.1 pIC50 8000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
ChEMBL Inhibition of C-terminal His-tagged recombinant human HDAC3 (1 to 428 residues)/N-terminal GST-tagged recombinant human NCoR2 (395 to 489 residues) co-expressed in baculovirus infected Sf9 cells measured after 30 mins by fluorescence microplate reader assay B 5.3 pIC50 >5000 nM IC50 J Med Chem (2021) 64: 15280-15296 [PMID:34624191]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.9 pIC50 1270 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of recombinant human KDAC3/NcoR2 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay B 6.11 pIC50 770 nM IC50 J Med Chem (2016) 59: 1613-1633 [PMID:26681404]
histone deacetylase 4/Histone deacetylase 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3524] [GtoPdb: 2659] [UniProtKB: P56524]
ChEMBL Inhibition of C-terminal His-tagged/N-terminal GST-tagged recombinant human HDAC4 (627 to 1084 residues) expressed in Baculovirus infected insect cells using Boc-Lys(TFa)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay B 5.27 pKi 5380 nM Ki Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326]
ChEMBL Inhibition of HDAC4 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC4 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC4 using acetyl-Lys(trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of N-terminal GST-tagged human HDAC4 (627 to 1085 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC4 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of HDAC4 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.76 pIC50 17300 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC4 (unknown origin) measured after 30 mins by fluorescence microplate reader assay B 5.3 pIC50 >5000 nM IC50 J Med Chem (2021) 64: 15280-15296 [PMID:34624191]
ChEMBL Inhibition of human full length recombinant HDAC4 using p53 (379 to 382 residues) Ac-LGK(TFA)-AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 5.52 pIC50 3000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
ChEMBL Inhibition of HDAC4 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 5.96 pIC50 1100 nM IC50 J Med Chem (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 5/Histone deacetylase 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2563] [GtoPdb: 2660] [UniProtKB: Q9UQL6]
ChEMBL Inhibition of HDAC5 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC5 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC5 using acetyl-Lys(trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J Med Chem (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of C-terminal 6x-His tagged human HDAC5 (657 to 1123 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg Med Chem Lett (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC5 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2021) 221: 113526-113526 [PMID:33992929]
ChEMBL Inhibition of HDAC5 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of HDAC5 (unknown origin) measured after 30 mins by fluorescence microplate reader assay B 5.3 pIC50 >5000 nM IC50 J Med Chem (2021) 64: 15280-15296 [PMID:34624191]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.47 pIC50 3350 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC5 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 5.64 pIC50 2300 nM IC50 J Med Chem (2013) 56: 1772-1776 [PMID:23368884]
ChEMBL Inhibition of human full length recombinant HDAC5 using p53 (379 to 382 residues) Ac-LGK(TFA)-AMC as substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 2 hrs by fluorescence method B 6 pIC50 1000 nM IC50 J Med Chem (2020) 63: 12460-12484 [PMID:32608981]
histone deacetylase 6/Histone deacetylase 6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1865] [GtoPdb: 2618] [UniProtKB: Q9UBN7]
ChEMBL Inhibition of N-terminal GST-tagged recombinant human HDAC6 (1 to 1215 residues) expressed in Baculovirus infected insect cells using Boc-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubation for 90 mins measured after 15 mins by microplate reader based fluorescence assay B 8 pKi 10 nM Ki Bioorg Med Chem (2019) 27: 115036-115036 [PMID:31431326]
ChEMBL Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus-infected Sf9 insect cells using RHKK(Ac)AMC as substrate after 90 mins by fluorimeter B